863770-87-0

Usage

Uses

Used in Pharmaceutical Synthesis:
2-Phenyl-6-aminoquinoline is used as a key intermediate in the synthesis of various pharmaceuticals and organic compounds. Its unique structural features and reactivity make it a valuable component in the development of new drugs and therapeutic agents.
Used in Drug Discovery and Development:
Due to its potential biological and pharmacological activities, 2-Phenyl-6-aminoquinoline is utilized as a starting material in drug discovery and development processes. Researchers explore its properties to create novel compounds with therapeutic potential for treating a range of diseases.
Used in Disease Treatment:
2-Phenyl-6-aminoquinoline has been studied for its potential use in the treatment of various diseases. Its biological activities are of interest to scientists who aim to develop new treatments or improve existing ones for specific medical conditions.
Used as an Enzyme Inhibitor:
2-Phenyl-6-aMinoquinoline has also been investigated for its potential as an inhibitor of certain enzymes and biological processes. By targeting specific enzymes, 2-Phenyl-6-aminoquinoline may contribute to the regulation of disease-causing pathways, offering a new approach to managing certain health conditions.

Upstream product

• 98-80-6 phenylboronic acid 
• 29969-57-1 2-chloro-6-nitroquinoline 
• 1257303-36-8 N-(diphenylmethylene)-2-phenylquinolin-6-amine 
• 153164-25-1 6-nitro-2-phenyl-quinoline 
• 109540-22-9 6-amino-2-phenyl-quinoline-4-carboxylic acid 

Downstream Products

• 1257303-37-9 N-(5-bromo-2-chloropyrimidin-4-yl)-2-phenylquinolin-6-amine 
• 56162-63-1 6-phenyl-2-hydroxypyridine-3-carboxylic acid 
• 36861-71-9 3,8-diphenyl-[4,7]phenanthroline-1-carboxylic acid 

Relevant academic research and scientific papers

AHR INHIBITORS AND USES THEREOF

The present invention provides compounds useful as inhibitors of AHR, compositions thereof, and methods of using the same.

PYRIMIDINE INHIBITORS OF KINASE ACTIVITY

Described herein are compounds of formula (I) or pharmaceutical acceptable salts or solvates thereof, wherein L1, R1, R2, R3, R4, R5, and m are defined in the description. Methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as IGF-IR are also disclosed.

Novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production

Heterocyclic amidines with anti-inflammatory and analgesic activity that inhibit nitrogen oxide production, of formula (I): in which:G1 and G2 are hydrogen, halogen, hydroxyl, C1-C4 alkoxy, C1-C4 alkyl, and an amidino substituent of formula Q, provided that, for each compound of formula (I), only one of the two substituents G1 or G2 is an amidino substituent of formula Q: and in which the substituents W, Y and X are combined to form 9- or 10-membered bicyclic heteroaromatic derivatives containing up to 2 hetero atoms in the same ring; andZ is an aryl or heteroaryl group, a linear or branched C1-C6 alkyl or alkenyl chain, a C1-C4 alkyl-aryl group or a C1-C4 alkyl-heteroaryl group.

Novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production

Heterocyclic amidines with anti-inflammatory and analgesic activity that inhibit nitrogen oxide production, of formula (I): in which: G1 and G2 are hydrogen, halogen, hydroxyl, C1-C4 alkoxy, C1-C4 alkyl, and an amidino substituent of formula Q, provided that, for each compound of formula (I), only one of the two substituents G1 or G2 is an amidino substituent of formula Q: and in which the substituents W, Y and X are combined to form 9- or 10-membered bicyclic heteroaromatic derivatives containing up to 2 hetero atoms in the same ring; and Z is an aryl or heteroaryl group, a linear or branched C1-C6 alkyl or alkenyl chain, a C1-C4 alkyl-aryl group or a C1-C4 alkyl-heteroaryl group.